"The US FDA approval of [bevacizumab-nwgd] is a significant milestone—our seventh biosimilar approved in the US and a strong addition to our robust oncology portfolio," said Shreehas Tambe, chief executive officer and managing director at Biocon Biologics Ltd. "It underscores the depth of our scientific expertise and commitment to expanding access to high-quality, affordable biologics. We look forward to working with all stakeholders to bring more treatment options to patients."